Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-to-severe papulopustular rosacea in adults.

Poster highlights include: 

• Long-term safety and efficacy data from the open-label extension of two Phase 3 studies (Study 04 and Study 05) of FMX101 in patients with moderate-to-severe acne for a total treatment period of up to 52 weeks. 
• Data from three 12-week Phase 3 studies (FX2014-04, FX2014-05, and FX2017-22) that showed the safety and tolerability of FMX101 in pediatric patients (ages 9 - 17) with moderate-to-severe acne. 
• An ex-vivo permeation and penetration assessment in human skin, in which FMX101 and FMX103 delivered similar concentrations of minocycline to the epidermis and sebaceous appendage.

Foamix will present results of a comparative trial of FMX101 versus five commercially available acne treatments in miscibility with sebum. Additionally, Foamix will present study endpoints achieved with FMX103 in patients with moderate-to-severe papulopustular rosacea in two Phase 3 12-week pivotal clinical studies (FX2016-11 and FX2016-12).